Publications

The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muslce apoptosis and ultrastructural defects in Col6a1-/- mypathic mice

The Cyclophilin Inhibitor Debio 025 Combined with PEG IFNα2a Significantly Reduces Viral Load in Teatment-Naïve Hepatitis C Patients

Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference

Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type

Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a…

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with…

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with…

Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent